Acute and Chronic Inflammatory Indications
Acute Inflammatory Indications
TREM-1 is an amplifier of innate immune response. Its activation is mediated following infection with different types of pathogens, as well as following non-infectious tissue damage. The TREM-1 receptor triggers dysregulation of immune response, regardless of the type of pathogen or tissue damaged.
Inotrem is developing a therapeutic solution based on nangibotide for septic shock patients. The pathophysiology of septic shock is characterized by an excessive systemic inflammatory reaction in response to a serious infection. Its consequences include the dysfunction of vital organs and major hemodynamic disorders that may prove fatal for patients. Activation of the TREM-1 pathway is recognized as a key factor contributing to septic shock.
Septic shock is a global health priority. It affects up to 1% of the population annually with a mortality rate of up to 50%, placing it as the 1st cause of death in intensive care units in developed countries. Inotrem’s therapeutic solution has the potential to become the first causal treatment for septic shock.
Actively engaged to fight the worldwide COVID-19 pandemic, Inotrem is also working on a treatment for patients in Intensive Care Units (ICUs) suffering from severe forms of COVID-19. This therapeutic program was declared “National Priority Research” by the French government. As in septic shock, the severe forms of COVID-19 are characterized by the dysregulated inflammatory reaction responsible for the respiratory distress that lead many patients to the critical care unit. In that setting as well, the TREM-1 pathway is recognized as a key contributing factor to the severity of the disease.
Covid-19 is a new pandemic disease with acute respiratory syndrome. Mortality of COVID-19 patients is reported to be between 25% and 35% in critical care units. To this day, no specific therapy exists for critically ill COVID-19 patients.
Acute inflammation caused by severe tissue injury
Beyond severe infections, the TREM-1 pathway is also engaged when there is a severe tissue injury that induces a massive release of danger signals. Inotrem research group as well as independent academic works have confirmed that TREM-1 engagement promotes a dysregulated response that has the potential to worsen the severity of the initial insult in clinical situations such as ischemia/reperfusion after myocardial infarction, poly-traumatism, and stroke. Ischemia-reperfusion injury post myocardial infarction will be the first non-infectious conditions to be tested with nangibotide H1 2022.
Chronic Inflammatory Indications
Further expanding on its technology platform, Inotrem has launched two programs focusing on a new therapeutic modality targeting chronic inflammatory processes. In parallel to these developments, Inotrem is conducting various translational research and medicine programs to identify the most attractive pathology to demonstrate the biological and clinical activity of the new entities.